Pasquale S A
Department of Obstetrics and Gynecology, UMDNJ--Robert Wood Johnson Medical School, New Brunswick.
Int J Fertil. 1986;31 SU [UPDATE]:13-9.
The association of progestogen and estrogen with certain undesirable effects led investigators to seek oral contraceptive (OC) formulations containing reduced amounts of both. Evidence is presented from studies of the triphasic regimen of 0.5 mg norethindrone plus 35 micrograms ethinyl estradiol on the first seven menstrual cycle days, 0.75 mg norethindrone plus 35 micrograms ethinyl estradiol the second seven days, followed by 1 mg norethindrone plus 35 micrograms ethinyl estradiol for the final seven days. This OC formulation appears to be highly effective and relatively free of the side effects commonly associated with low-dose OC regimens.
孕激素和雌激素与某些不良影响的关联促使研究人员寻找两种激素含量均降低的口服避孕药（OC）配方。有研究对三相方案进行了论证，即在前七个月经周期日服用0.5毫克炔诺酮加35微克炔雌醇，第二个七天服用0.75毫克炔诺酮加35微克炔雌醇，最后七天服用1毫克炔诺酮加35微克炔雌醇。这种OC配方似乎非常有效，且相对没有低剂量OC方案常见的副作用。
